Successful Treatment of Carbapenem-Resistant Acinetobacter baumannii Infection with Sulbactam-Durlobactam: A Two-Case Report
Abstract
Background: Sulbactam-Durlobactam (SUL-DUR), a novel β-lactam/β-lactamase inhibitor combination, exhibits potent activity against Acinetobacter baumannii isolates, including carbapenem-resistant Acinetobacter baumannii (CRAB). Current guidelines recommend SUL-DUR in combination with imipenem-cilastatin or meropenem for the treatment of CRAB pneumonia. However, clinical evidence regarding its use in CRAB bloodstream infections remains limited, and the role of SUL-DUR monotherapy in CRAB pneumonia remains unclear.
Methods: We describe two critically ill patients with severe CRAB infections who were successfully treated with SUL-DUR. Clinical characteristics, microbiological findings, antimicrobial regimens, treatment responses, and clinical outcomes were reviewed. The rationale for selecting combination therapy or monotherapy was described according to infection characteristics and individual clinical considerations.
Results: The first patient developed CRAB bloodstream infection following severe trauma and was successfully treated with SUL-DUR combined with imipenem-cilastatin, achieving rapid clearance of blood cultures and clinical improvement. The second patient developed CRAB pneumonia in the context of pulmonary Aspergillus fumigatus infection requiring antifungal therapy. Considering the absence of concurrent bacterial pathogens and concerns regarding additional broad-spectrum antimicrobial exposure, SUL-DUR monotherapy was selected as an individualized treatment…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.